Literature DB >> 11904752

Vascular fibrosis and calcification in the hippocampus in aging, Alzheimer disease, and Down syndrome.

J Wegiel1, I Kuchna, T Wisniewski, M J de Leon, B Reisberg, T Pirttila, T Kivimaki, T Lehtimaki.   

Abstract

Study of the hippocampal formation of 82 subjects, including 25 control subjects from 33 to 83 years of age, 34 subjects with Alzheimer disease (AD) from 65 to 89 years of age, and 23 subjects with Down syndrome (DS) from 33 to 72 years of age, revealed hippocampal vasculopathy with fibrosis and calcification (VFC) in 40% of control, 59% of AD, and 4% of DS subjects. VFC starts in the precapillaries/capillaries in the molecular layer of the dentate gyrus (DG) and expands to the granule cell and polymorphic cell layer of the DG, and to the stratum lacunosum/molecular in the CA1 sector. Vasculopathy spreads from the tail to the body and, in a few cases, to the head of the hippocampal formation. Light and electron microscopy reveal thickening of the vascular wall with fibrosis, calcification, and enforcement of the astrocyte interface with vessels with anchorage densities associated with hemidesmosome-like structures. In moderately and severely affected cases, fragmentation and removal of calcified and occluded vessels result in local reduction of vascular network. In two AD subjects, severe vascular calcification extending from the tail to the head of the hippocampal formation was associated with loss of almost all neurons in the CA1 sector and in the subiculum proper, corresponding to hippocampal sclerosis. The topography of affected vessels and the patterns of neuronal loss reflect the middle hippocampal artery distribution with its precapillary/capillary network. The similar prevalence of vasculopathy in the AD group and in the age-matched control group, and the presence of hippocampal VFC in only one subject in the DS cohort, 96% of which is affected by Alzheimer-type pathology, oppose the link between AD and this form of vasculopathy. However, severe VFC affects the pattern of AD pathology locally by deletion of neurofibrillary degeneration and beta-amyloidosis in the CA1 sector, subiculum proper, and the molecular layer of the dentate gyrus. Hippocampal VFC appears to be a form of vascular pathology with a unique predilection for the middle hippocampal artery and corresponding capillary network, which results in patchy neuronal loss in moderately affected subjects and in almost total neuronal loss in the area of impaired blood supply in severely affected subjects. These observations suggest an etiologic link between hippocampal VFC and hippocampal sclerosis.

Entities:  

Mesh:

Year:  2001        PMID: 11904752     DOI: 10.1007/s00401-001-0471-y

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  10 in total

1.  Multiregional Age-Associated Reduction of Brain Neuronal Reserve Without Association With Neurofibrillary Degeneration or β-Amyloidosis.

Authors:  Jerzy Wegiel; Michael Flory; Izabela Kuchna; Krzysztof Nowicki; Shuang Yong Ma; Jarek Wegiel; Eulalia Badmaev; Wayne P Silverman; Mony de Leon; Barry Reisberg; Thomas Wisniewski
Journal:  J Neuropathol Exp Neurol       Date:  2017-06-01       Impact factor: 3.685

2.  Measurement of hippocampal subfields and age-related changes with high resolution MRI at 4T.

Authors:  S G Mueller; L Stables; A T Du; N Schuff; D Truran; N Cashdollar; M W Weiner
Journal:  Neurobiol Aging       Date:  2006-05-19       Impact factor: 4.673

3.  Isolation of mineralizing Nestin+ Nkx6.1+ vascular muscular cells from the adult human spinal cord.

Authors:  Daria Mamaeva; Chantal Ripoll; Claire Bony; Marisa Teigell; Florence E Perrin; Bernard Rothhut; Ivan Bieche; Rosette Lidereau; Alain Privat; Valérie Rigau; Hélène Guillon; Florence Vachiery-Lahaye; Daniele Noel; Luc Bauchet; Jean-Philippe Hugnot
Journal:  BMC Neurosci       Date:  2011-10-10       Impact factor: 3.288

4.  Hippocampal sclerosis dementia differs from hippocampal sclerosis in frontal lobe degeneration.

Authors:  Catalina Amador-Ortiz; Zeshan Ahmed; Cynthia Zehr; Dennis W Dickson
Journal:  Acta Neuropathol       Date:  2006-12-30       Impact factor: 17.088

5.  Hippocampal Calcification on Computed Tomography in Relation to Cognitive Decline in Memory Clinic Patients: A Case-Control Study.

Authors:  Remko Kockelkoren; Jill B De Vis; Willem P Th M Mali; Jeroen Hendrikse; Pim A de Jong; Annemieke M Rozemuller; Huiberdina L Koek
Journal:  PLoS One       Date:  2016-11-28       Impact factor: 3.240

6.  Osteopontin and phospho-SMAD2/3 are associated with calcification of vessels in D-CAA, an hereditary cerebral amyloid angiopathy.

Authors:  Laure Grand Moursel; Linda M van der Graaf; Marjolein Bulk; Willeke M C van Roon-Mom; Louise van der Weerd
Journal:  Brain Pathol       Date:  2019-04-04       Impact factor: 6.508

Review 7.  The Interplay Between Brain Vascular Calcification and Microglia.

Authors:  Upasana Maheshwari; Sheng-Fu Huang; Sucheta Sridhar; Annika Keller
Journal:  Front Aging Neurosci       Date:  2022-03-02       Impact factor: 5.750

8.  Histological validation of calcifications in the human hippocampus as seen on computed tomography.

Authors:  Melissa E M Peters; Remko Kockelkoren; Esther J M de Brouwer; Huiberdina L Koek; Ronald L A W Bleys; Willem P Th M Mali; Jeroen Hendrikse; Annemieke M Rozemuller; Pim A de Jong
Journal:  PLoS One       Date:  2018-05-11       Impact factor: 3.240

9.  Hippocampal calcification on brain CT: prevalence and risk factors in a cerebrovascular cohort.

Authors:  Remko Kockelkoren; Jill B De Vis; M Stavenga; Willem P Th M Mali; Jeroen Hendrikse; Annemieke M Rozemuller; Huiberdina L Koek; Irene C van der Schaaf; Birgitta K Velthuis; Pim A de Jong
Journal:  Eur Radiol       Date:  2018-04-04       Impact factor: 5.315

10.  SWI and phase imaging reveal intracranial calcifications in the P301L mouse model of human tauopathy.

Authors:  Ruiqing Ni; Yvette Zarb; Gisela A Kuhn; Ralph Müller; Yankey Yundung; Roger M Nitsch; Luka Kulic; Annika Keller; Jan Klohs
Journal:  MAGMA       Date:  2020-05-28       Impact factor: 2.310

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.